DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes

This study is comparing two diabetes medications — dapagliflozin and pioglitazone — added to standard treatment in people with type 2 diabetes whose blood sugar is not fully controlled on metformin and a DPP-4 inhibitor. **You may be eligible if...** - You are 19 or older with type 2 diabetes - You have been on a stable dose of metformin and a DPP-4 inhibitor (a common diabetes pill) for at least 8 weeks - Your HbA1c (a 3-month average blood sugar measure) is between 7.0% and 10% - Your BMI is between 18.5 and 40 **You may NOT be eligible if...** - You have type 1 diabetes - Your BMI is above 40 - You have moderate to severe kidney disease (stage 3b or worse) - You have severe liver or heart problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.